Internal Medicine · San Diego, CA
NPI
1861492738
Since 2005
Specialty
Internal Medicine
Code 207R00000X
Group practices
2
Medicare group memberships
Hospitals
3
Hospital affiliations
6367 Alvarado Ct, Suite 200
San Diego, CA, 92120
Phone (619) 583-1954
Groups this clinician bills Medicare through
Medicare paid, 2024
$1.2M
14,509 services
Medicare patients, 2024
862
Average age 66
Drug cost, 2024
$4.6M
28,499 prescriptions
Company payments, 2025
$3,911
From 41 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Bernard A Michlin was code 99214 (office e&m - established), 2,771 times for 440 patients. In total Bernard A Michlin billed 14,509 services in 31 codes, and Medicare paid $1.2M.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2021-05-25.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99214 Office E&M - Established | Office | 2,771 | 440 | $99.08 | $275K |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 1,980 | 401 | $13.40 | $27K |
| 99490 Chronic, Principal, and Transitional Care Management | Office | 1,877 | 547 | $51.46 | $97K |
| 99309 SNF E&M | Facility | 1,546 | 263 | $87.03 | $135K |
| 99439 Chronic, Principal, and Transitional Care Management | Office | 1,062 | 327 | $40.26 | $43K |
| 99489 Chronic, Principal, and Transitional Care Management | Office | 773 | 194 | $62.06 | $48K |
| 99483 Office/Outpatient Services | Office | 682 | 681 | $224.55 | $153K |
| 99487 Chronic, Principal, and Transitional Care Management | Office | 677 | 334 | $115.62 | $78K |
| G0439 Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 661 | 661 | $138.52 | $92K |
| 99310 SNF E&M | Facility | 326 | 108 | $126.68 | $41K |
| 99211 Office E&M - Established | Office | 276 | 36 | $20.76 | $5,731 |
| 99233 Hospital E&M - Subsequent | Facility | 257 | 63 | $96.28 | $25K |
| 99491 Chronic, Principal, and Transitional Care Management | Office | 253 | 201 | $70.93 | $18K |
| 99306 SNF E&M | Facility | 199 | 142 | $148.26 | $30K |
| 99497 Care Management/Coordination | Office | 181 | 166 | $64.87 | $12K |
By year: 2022 $943K for 10,577 services; 2023 $1.1M for 12,071 services; 2024 $1.2M for 14,509 services.
Medicare prescription drug claims, 2024
In 2024, the drug Bernard A Michlin prescribed most often to Medicare patients was Levothyroxine Sodium, with 1,448 prescriptions and refills. In total Bernard A Michlin wrote 28,499 Medicare prescriptions that cost $4.6M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Levothyroxine Sodium Generic | 1,448 | 1,661 | 166 | $16K |
| Atorvastatin Calcium Generic | 1,367 | 1,596 | 212 | $17K |
| Amlodipine Besylate Generic | 931 | 1,326 | 155 | $7,424 |
| Lisinopril Generic | 849 | 1,236 | 156 | $7,852 |
| Farxiga Dapagliflozin Propanediol | 545 | 624 | 79 | $272K |
| Gabapentin Generic | 517 | 591 | 86 | $12K |
| Tamsulosin Hcl Generic | 515 | 660 | 92 | $9,246 |
| Metoprolol Tartrate Generic | 501 | 618 | 80 | $3,535 |
| Metformin Hcl Generic | 497 | 560 | 69 | $5,549 |
| Losartan Potassium Generic | 456 | 754 | 99 | $4,959 |
| Mirtazapine Generic | 442 | 470 | 76 | $10K |
| Rosuvastatin Calcium Generic | 435 | 826 | 98 | $8,800 |
| Trazodone Hcl Generic | 433 | 535 | 79 | $5,489 |
| Eliquis Apixaban | 408 | 446 | 51 | $171K |
| Omeprazole Generic | 383 | 479 | 66 | $4,896 |
Brand drugs: 6,102 claims; generic drugs: 22,233 claims; opioid claims: 202.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Bernard A Michlin $3,911 ($3,911 in general payments such as food, travel and fees) from 41 companies. The largest payer was Vanda Pharmaceuticals Inc. with $534.
| Company | Payments | Amount |
|---|---|---|
| Vanda Pharmaceuticals Inc. VNDA | 16 | $534 |
| UCB, Inc. UCB.BR | 22 | $309 |
| Neurocrine BioSciences, Inc. NBIX | 7 | $261 |
| Abbvie Inc. ABBV | 14 | $234 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) JNJ | 10 | $216 |
| Bayer Healthcare Pharmaceuticals Inc. BAYN.DE | 7 | $205 |
| Axsome Therapeutics, Inc. AXSM | 4 | $193 |
| Pfizer Inc. PFE | 14 | $145 |
| AstraZeneca Pharmaceuticals LP AZN | 8 | $143 |
| Neurelis, Inc. | 16 | $140 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.